NO960309L - Agonists and antagonists of human interleukin-10 - Google Patents
Agonists and antagonists of human interleukin-10Info
- Publication number
- NO960309L NO960309L NO960309A NO960309A NO960309L NO 960309 L NO960309 L NO 960309L NO 960309 A NO960309 A NO 960309A NO 960309 A NO960309 A NO 960309A NO 960309 L NO960309 L NO 960309L
- Authority
- NO
- Norway
- Prior art keywords
- agonists
- antagonists
- human
- human interleukin
- preparations
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Agonister og antagonister for humant IL-10 er tilveiebrakt ved hjelp av denne oppfinnelsen som er basert på modifikasjon av endene til fullstendig, | humant IL-10. Det er også tilveiebrakt j preparater og fremgangsmåter for til- i førsel eller inhibering av den biolog- iske aktivitet av humant IL-10. Slike preparater kan være anvendbare ved be- handlingen av sykdommer kjennetegnet ved upassende Th-responser. Nuklein- syrer som koder for agonistene og antagonistene, rekombinante vektorer og : transformerte vertsceller som omfatter j slike nukleinsyrer, og fremgangsmåter i for fremstilling av agonistene og 1 antagonistene under anvendelse av de transformerte vertsceller, er også til- veiebrakt.Agonists and antagonists for human IL-10 are provided by this invention based on modification of the ends to complete, | human IL-10. Preparations and methods are also provided for the delivery or inhibition of the biological activity of human IL-10. Such preparations may be useful in the treatment of diseases characterized by inappropriate Th responses. Nucleic acids encoding the agonists and antagonists, recombinant vectors and: transformed host cells comprising such nucleic acids, and methods for preparing the agonists and 1 antagonists using the transformed host cells, are also provided.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9894393A | 1993-07-26 | 1993-07-26 | |
PCT/US1994/008052 WO1995003411A1 (en) | 1993-07-26 | 1994-07-22 | Agonists and antagonists of human interleukin-10 |
Publications (2)
Publication Number | Publication Date |
---|---|
NO960309D0 NO960309D0 (en) | 1996-01-25 |
NO960309L true NO960309L (en) | 1996-01-25 |
Family
ID=22271670
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO960309A NO960309L (en) | 1993-07-26 | 1996-01-25 | Agonists and antagonists of human interleukin-10 |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0711346A1 (en) |
JP (1) | JPH08507930A (en) |
KR (1) | KR960704041A (en) |
CN (1) | CN1127529A (en) |
AU (1) | AU681178B2 (en) |
CA (1) | CA2168110A1 (en) |
CZ (1) | CZ23396A3 (en) |
FI (1) | FI960353A0 (en) |
HU (1) | HUT73463A (en) |
IL (1) | IL110413A0 (en) |
NO (1) | NO960309L (en) |
NZ (1) | NZ269663A (en) |
PL (1) | PL312718A1 (en) |
SG (1) | SG43798A1 (en) |
SK (2) | SK150596A3 (en) |
WO (1) | WO1995003411A1 (en) |
ZA (1) | ZA945434B (en) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6159937A (en) | 1994-07-05 | 2000-12-12 | Steeno Research Group A/S | Immunomodulators |
GB2304047A (en) | 1995-08-09 | 1997-03-12 | Univ Manchester | Pharmaceutical compositions containing cytokines |
AUPN481295A0 (en) * | 1995-08-16 | 1995-09-07 | Medvet Science Pty. Ltd. | Agonists of haemopoietic growth factors |
AU4385696A (en) | 1996-01-18 | 1997-08-11 | Christian Gronhoj Larsen | Synthetic il-10 analogues |
DE19851675A1 (en) * | 1998-11-10 | 2000-05-11 | Bayer Ag | Human interleukin-10 mutant proteins |
AU8729101A (en) | 2000-03-31 | 2001-10-15 | Idec Pharma Corp | Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for the treatment of B cell lymphoma |
EP2295450B1 (en) | 2000-09-29 | 2015-01-28 | Merck Sharp & Dohme Corp. | Pegylated interleukin-10 |
US7261882B2 (en) | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
EP1712241A1 (en) | 2005-04-15 | 2006-10-18 | Centre National De La Recherche Scientifique (Cnrs) | Composition for treating cancer adapted for intra-tumoral administration and uses thereof |
HUE041875T2 (en) | 2005-05-31 | 2019-06-28 | Univ Colorado Regents | Methods for delivering genes |
WO2008054585A2 (en) | 2006-09-28 | 2008-05-08 | Schering Corporation | Use of pegylated il-10 to treat cancer |
AU2009298131B2 (en) | 2008-10-02 | 2016-07-14 | Aptevo Research And Development Llc | CD86 antagonist multi-target binding proteins |
PT2379115T (en) | 2008-12-17 | 2018-01-03 | Merck Sharp & Dohme | Mono- and di-peg il-10 production; and uses |
EP2776460B1 (en) | 2011-11-08 | 2018-05-02 | UMC Utrecht Holding B.V. | Fusion protein comprising an interleukin 4 and interleukin 10 |
AU2014254019B2 (en) | 2013-04-18 | 2018-09-27 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
JP2016526014A (en) * | 2013-04-24 | 2016-09-01 | アルモ・バイオサイエンシーズ・インコーポレイテッド | Interleukin-10 composition and use thereof |
ES2688206T3 (en) | 2013-06-17 | 2018-10-31 | Armo Biosciences, Inc. | Procedure for assessing protein identity and stability |
CN105658232A (en) | 2013-08-30 | 2016-06-08 | 阿尔莫生物科技股份有限公司 | Methods of using interleukin-10 for treating diseases and disorders |
ES2862139T3 (en) | 2013-11-11 | 2021-10-07 | Armo Biosciences Inc | Procedures for the use of Interleukin 10 for the treatment of diseases and disorders |
CN106573072A (en) | 2014-06-02 | 2017-04-19 | 阿尔莫生物科技股份有限公司 | Methods of lowering serum cholesterol |
JP2017536098A (en) | 2014-10-14 | 2017-12-07 | アルモ・バイオサイエンシーズ・インコーポレイテッド | Interleukin-15 composition and use thereof |
KR20170084033A (en) | 2014-10-22 | 2017-07-19 | 아르모 바이오사이언시스 인코포레이티드 | Methods of using interleukin-10 for treating diseases and disorders |
WO2016126615A1 (en) | 2015-02-03 | 2016-08-11 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
CN107847583A (en) | 2015-05-28 | 2018-03-27 | 阿尔莫生物科技股份有限公司 | PEGylated Interleukin 10 for treating cancer |
US10398761B2 (en) | 2015-08-25 | 2019-09-03 | Armo Biosciences, Inc. | Methods of using combinations of PEG-IL-10 and IL-15 for treating cancers |
GB2620875B (en) | 2019-04-19 | 2024-05-08 | Synerkine Pharma B V | A fusion protein comprising IL13 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01113229A (en) * | 1987-10-27 | 1989-05-01 | Inahata Kenkyusho:Kk | Porous material of honeycomb structure |
IL94878A (en) * | 1989-06-28 | 2003-01-12 | Schering Corp | Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same |
ES2138976T3 (en) * | 1991-08-06 | 2000-02-01 | Schering Corp | USE OF INTERLEUKIN-10 ANALOGS OR ANTAGONISTS TO TREAT ENDOTOXIN OR SUPERANTIGEN INDUCED TOXICITY. |
-
1994
- 1994-07-22 PL PL94312718A patent/PL312718A1/en unknown
- 1994-07-22 CA CA002168110A patent/CA2168110A1/en not_active Abandoned
- 1994-07-22 ZA ZA945434A patent/ZA945434B/en unknown
- 1994-07-22 NZ NZ269663A patent/NZ269663A/en unknown
- 1994-07-22 JP JP7505238A patent/JPH08507930A/en active Pending
- 1994-07-22 WO PCT/US1994/008052 patent/WO1995003411A1/en not_active Application Discontinuation
- 1994-07-22 EP EP94923956A patent/EP0711346A1/en not_active Withdrawn
- 1994-07-22 SK SK1505-96A patent/SK150596A3/en unknown
- 1994-07-22 SK SK83-96A patent/SK8396A3/en unknown
- 1994-07-22 HU HU9503983A patent/HUT73463A/en unknown
- 1994-07-22 CN CN94192880A patent/CN1127529A/en active Pending
- 1994-07-22 AU AU73996/94A patent/AU681178B2/en not_active Ceased
- 1994-07-22 IL IL11041394A patent/IL110413A0/en unknown
- 1994-07-22 SG SG1996000969A patent/SG43798A1/en unknown
- 1994-07-22 CZ CZ96233A patent/CZ23396A3/en unknown
- 1994-07-22 KR KR1019960700358A patent/KR960704041A/en not_active Application Discontinuation
-
1996
- 1996-01-25 NO NO960309A patent/NO960309L/en unknown
- 1996-01-26 FI FI960353A patent/FI960353A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR960704041A (en) | 1996-08-31 |
HU9503983D0 (en) | 1996-03-28 |
SK150596A3 (en) | 1997-04-09 |
CN1127529A (en) | 1996-07-24 |
PL312718A1 (en) | 1996-05-13 |
EP0711346A1 (en) | 1996-05-15 |
NO960309D0 (en) | 1996-01-25 |
NZ269663A (en) | 1997-09-22 |
SK8396A3 (en) | 1997-03-05 |
WO1995003411A1 (en) | 1995-02-02 |
ZA945434B (en) | 1995-01-23 |
AU7399694A (en) | 1995-02-20 |
IL110413A0 (en) | 1994-10-21 |
FI960353A (en) | 1996-01-26 |
JPH08507930A (en) | 1996-08-27 |
CA2168110A1 (en) | 1995-02-02 |
AU681178B2 (en) | 1997-08-21 |
FI960353A0 (en) | 1996-01-26 |
HUT73463A (en) | 1996-08-28 |
CZ23396A3 (en) | 1996-05-15 |
SG43798A1 (en) | 1997-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO960309L (en) | Agonists and antagonists of human interleukin-10 | |
RU95115239A (en) | Erythropoietin analog | |
NO952974L (en) | G-CSF analog preparations and methods | |
DE68929043D1 (en) | DNA ENCODING ANDROGEN RECEPTOR PROTEIN | |
DK43890D0 (en) | NUCLEIC ACID, VECTORS AND CELLS CONTAINING THE PRODUCED PRODUCTS AND THEIR USE THEREOF | |
WO2000034317A3 (en) | Method for reducing immunogenicity of proteins | |
NO177678C (en) | Method for Preparing a Therapeutically Active, Recombinant Protein having ASP Activity, Expression System, and DNA Encoding the Protein | |
CA2080462A1 (en) | Therapeutic uses of actin-binding compounds | |
NZ279963A (en) | Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946 | |
NO177716C (en) | Method for Preparation of Therapeutically Active Polypeptides, DNA Sequence, Expression Vector and Antibody | |
ES2084045T3 (en) | BACTERIA THAT HOST VECTOR OF EXPRESSION THAT CODES THE HUMAN CILIAR NEUROTROPHIC FACTOR (H-CNTF), ITS USE IN THE PRODUCTION OF H-CNTF, ANTIBODIES FOR H-CNTF AND THE USE OF H-CNTF IN MEDICAL TREATMENT. | |
DK1025236T3 (en) | Human checkpoint kinase, HCDS1, preparations and methods | |
DE59610632D1 (en) | VARIANTS OF THE HUMAN RECOMBINANT INTERFERON GAMMA (RHU-IFN-GAMMA) WITH INCREASED THERMAL STABILITY | |
AU6745287A (en) | Dna sequences coding for proteins having the biological activity of husi-type i inhibitors, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins | |
EA200001124A1 (en) | METHOD OF GENE THERAPY | |
NZ335633A (en) | Production of recombinant H. pylori polypeptides for treatment and diagnosis of H. pylori related diseases | |
ATE310828T1 (en) | IMPLANT AND VECTOR FOR THE TREATMENT OF ACQUIRED DISEASES | |
ATE374246T1 (en) | POLYPEPTIDE FRAGMENTS WITH A C-TERMINAL PART OF CATALASE FROM HELICOBACTER | |
NO890174L (en) | RECOMBINANT INTERLEUKIN-1ALFA POLYPEPTIDES. | |
PT90739A (en) | METHOD FOR PREPARING A PROTEIN PROVIDED WITH TROMBIN INABICATION ACTIVITY | |
DK0805204T3 (en) | Biticle - specifically receptor protein and its use | |
ATE103979T1 (en) | HUMAN LYMPHOTOXIN. | |
AU2927689A (en) | Cucumber mosaic virus coat protein gene | |
AU1318797A (en) | Peptides and uses thereof for therapy of celiac diseases | |
DK595187A (en) | MINACTIVIN AND METHOD OF PRODUCING THEREOF |